PLIVA Announces H1 2008 Results
- Details
- Category: Financial
PLIVA d.d. (ZSE: PLVA-R-A), a subsidiary of Barr Pharmaceuticals, Inc. ("Barr"), today reported financial results for the six month period ended 30 June 2008, prepared in accordance with International Financial Reporting Standards (IFRS).
Nycomed's preclinical anti-cancer program sold to Bayer Schering Pharma
- Details
- Category: Nycomed
Nycomed agreed with Bayer Schering Pharma on the sale of the preclinical anti-cancer program. The agreement is part of Nycomed's strategic decision not to further invest in oncology R&D activities. As the final step in the divestment of its Oncology portfolio, Nycomed agreed with Bayer Schering Pharma on the sale of a kinase inhibitor program, targeting a key growth and survival pathway in cancer.
Lipitor 80 mg Reduced the Risk of Heart Attack and Stroke
- Details
- Category: Pfizer
Pfizer Inc announced that, in patients with heart disease, type 2 diabetes and chronic kidney disease, Lipitor® (atorvastatin calcium) 80 mg significantly reduced the risk of major cardiovascular events, including heart attack and stroke, by 35 percent compared with Lipitor 10 mg.
Closure of the tipranavir trials SPRING and TICINO
- Details
- Category: Boehringer Ingelheim
After careful consideration of the feasibility of meeting the enrolment targets for the SPRING (Safety, efficacy and pharmacokinetics of tipranavir boosted with low dose ritonavir (500mg/200mg) twice daily in 400 racially and gender diverse HIV-positive treatment-experienced population) and TICINO (safety and efficacy of tipranavir/ritonavir in treatment-experienced patients also infected with the hepatitis B or hepatitis C viruses) trials, Boehringer Ingelheim has terminated both studies.
Novo Nordisk employee suspended after being charged with insider trading
- Details
- Category: Novo Nordisk
Novo Nordisk has suspended one of its employees after the employee yesterday was charged by the Danish Public Prosecutor for Serious Economic Crime with unlawful insider trading in the company's shares.
First interleukin-6 inhibitor (IL-6) to offer new therapeutic option for rheumatoid arthritis
- Details
- Category: Roche
Roche announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) by a near unanimous (10-1) vote recommended approval of Actemra (tocilizumab), a novel interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody, for reducing the signs and symptoms in adults with moderate to severe rheumatoid arthritis (RA).
Significant blood pressure reductions seen with Exforge across difficult-to-treat groups
- Details
- Category: Novartis
New data show that Exforge, a single-pill combination of the world's leading high blood pressure medicines Diovan® (valsartan) and amlodipine, gets nearly twice as many patients with high baseline blood pressure to a healthier blood pressure goal compared to amlodipine alone[1].
More Pharma News ...
- GlaxoSmithKline and the Harvard Stem Cell Institute announce a unique collaboration
- Nexavar Approved for Treatment of Liver Cancer in China
- Nexavar Study Demonstrates Significant Improvement in Overall Survival
- Pfizer Reports Second-Quarter 2008 Results
- GlaxoSmithKline teams up with academia to develop new medicines of value
- Novartis gains momentum with strong performance in first half of 2008
- Abbott Reports Stronger-than-Expected Sales and Earnings Growth in Second Quarter